title: New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review).
abstract: Cases of endometrial cancer have increased in recent years, but the prognosis             of patients with this disease has also been improved by combined modality therapy             with surgery, radiotherapy and chemotherapy. However, the development of new therapy             is required from the perspectives of conservation of fertility and efficacy for             recurrent and intractable cancer. New candidate therapeutic agents for endometrial             cancer include fourth-generation progestins for inhibition of growth and differentiation             of endometrial glands; metformin for reduction of hTERT expression in the endometrium             and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition             of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1             cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis             and progression; and HDAC inhibitors that block the growth of cancer cells by             transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction             of apoptosis. In this study, we review the background and early clinical evidence             for these agents as new therapeutic candidates for endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine,                     Keio University, Tokyo 160-8582, Japan.
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Umene
authors.forename: Kouji
authors.initials: K
authors.lastname: Banno
authors.forename: Iori
authors.initials: I
authors.lastname: Kisu
authors.forename: Megumi
authors.initials: M
authors.lastname: Yanokura
authors.forename: Yuya
authors.initials: Y
authors.lastname: Nogami
authors.forename: Kosuke
authors.initials: K
authors.lastname: Tsuji
authors.forename: Kenta
authors.initials: K
authors.lastname: Masuda
authors.forename: Arisa
authors.initials: A
authors.lastname: Ueki
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamagami
authors.forename: Eiichiro
authors.initials: E
authors.lastname: Tominaga
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Susumu
authors.forename: Daisuke
authors.initials: D
authors.lastname: Aoki
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011372:Progestins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D056572:Histone Deacetylase Inhibitors; D035683:MicroRNAs; D011372:Progestins; D008687:Metformin